Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL22217135 | 1.00 | NR4A2 (0.45) | NR4A2TSHRKEAP1ALDH1A1GAA | |
| SCHEMBL27583154 | 0.94 | ALDH1A1 (0.50) | NR4A2TSHRKEAP1ALDH1A1GAA | |
| SCHEMBL4834310 | 0.89 | HDAC3 (0.47) | TSHRALDH1A1SMN1; SMN2CYP3A4LMNA | |
| SCHEMBL8584248 | 0.89 | HDAC3 (0.46) | TSHRKEAP1ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL404782 | 0.88 | ALDH1A1 (0.56) | TSHRALDH1A1PRSS1CTSGCTRB1 | |
| SCHEMBL8362103 | 0.87 | HDAC3 (0.50) | TSHRALDH1A1SMN1; SMN2LMNAHDAC3 | |
| SCHEMBL28433233 | 0.87 | HDAC3 (0.50) | TSHRALDH1A1SMN1; SMN2LMNAHDAC3 | |
| SCHEMBL3677991 | 0.86 | KDM4E (0.51) | NR4A2TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL27693888 | 0.84 | TSHR (0.50) | TSHRALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL3311087 | 0.84 | NR4A2 (0.55) | NR4A2TSHRKEAP1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119044-A2 | ADRULIPASE COMPOSITIONS | First Wave BioPharma, Inc. (US) | 2024-06-06 | — | — | WO | claimed |
| CN-116437947-A | Non-pig formulations and methods thereof | 第一浪潮生物制药有限公司 | 2023-07-14 | — | — | CN | claimed |
| WO-2023114390-A2 | LIPASE FORMULATIONS AND METHODS THEREOF | First Wave BioPharma, Inc. (US) | 2023-06-22 | — | — | WO | claimed |
| EP-4167970-A1 | NON-PORCINE FORMULATIONS AND METHODS THEREOF | First Wave Biopharma, Inc. (US) | 2023-04-26 | — | — | EP | claimed |
| EP-3972569-A1 | NANOPARTICLES COMPRISING ENZALUTAMIDE | Helm AG (DE) | 2022-03-30 | — | — | EP | claimed |
| WO-2021257843-A1 | NON-PORCINE FORMULATIONS AND METHODS THEREOF | AZURRX BIOPHARMA, INC. (US) | 2021-12-23 | — | — | WO | claimed |
| US-10940117-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | ARBOR PHARMACEUTICALS, LLC (US) | 2021-03-09 | — | — | US | claimed |
| WO-2020234448-A1 | NANOPARTICLES COMPRISING ENZALUTAMIDE | HELM AG (DE) | 2020-11-26 | — | — | WO | claimed |
| US-20200246271-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2020-08-06 | — | — | US | claimed |
| US-10716760-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | ARBOR PHARMACEUTICALS, LLC (US) | 2020-07-21 | — | — | US | claimed |
| US-20030091643-A1 | Amorphous mixture of acid sensitive drug and addition polymer; chemical resistance, stability | BEND RESEARCH, INC. | 2003-05-15 | — | — | US | claimed |
| US-20030072801-A1 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | PFIZER INC. | 2003-04-17 | — | — | US | claimed |
| US-20030054038-A1 | Pharmaceutical compositions of drugs and neutralized acidic polymers | BEND RESEARCH, INC. | 2003-03-20 | — | — | US | claimed |
| WO-2003000235-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUGS AND NEUTRAL POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | claimed |
| WO-2003000292-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND/OR ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | claimed |
| EP-1269994-A2 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | claimed |
| EP-1263414-A1 | PHARMACEUTICAL COMPOSITIONS OF GLYCOGEN PHOSPHORYLASE INHIBITORS | Pfizer Products Inc. (US) | 2002-12-11 | — | — | EP | claimed |
| US-20020103225-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | BEND RESEARCH INC. | 2002-08-01 | — | — | US | claimed |
| US-20010053778-A1 | Pharmaceutical compositions of glycogen phosphorylase inhibitors | BEND RESEARCH, INC. | 2001-12-20 | — | — | US | claimed |
| WO-2001068055-A1 | PHARMACEUTICAL COMPOSITIONS OF GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2001-09-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246271-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | FH, MGMT, BHMT2 | NR4A2 3761/4885TSHR 4205/4885KEAP1 1514/4885 |
| US-20030072801-A1 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | ABCB1, ABCG2, CYP3A7 | NR4A2 4004/4885TSHR 4833/4885KEAP1 4642/4885 |
| US-20030054038-A1 | Pharmaceutical compositions of drugs and neutralized acidic polymers | PDE7A, CA6, PDE9A | NR4A2 4780/4885TSHR 3687/4885KEAP1 4797/4885 |
| US-20020103225-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | CETP, HDLBP, NPC1L1 | NR4A2 3546/4885TSHR 4570/4885KEAP1 2914/4885 |
| US-20030091643-A1 | Amorphous mixture of acid sensitive drug and addition polymer; chemical resistance, stability | ABCC1, ABCG2, PGD | NR4A2 4347/4885TSHR 4633/4885KEAP1 4494/4885 |
| US-10940117-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | FH, MGMT, BHMT2 | NR4A2 3761/4885TSHR 4205/4885KEAP1 1514/4885 |
| US-20010053778-A1 | Pharmaceutical compositions of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | NR4A2 4606/4885TSHR 4671/4885KEAP1 3308/4885 |
| US-10716760-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | FH, MGMT, BHMT2 | NR4A2 3761/4885TSHR 4205/4885KEAP1 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.